New combo therapy shows promise for tough prostate cancer

NCT ID NCT03338790

Completed Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested the immunotherapy drug nivolumab (Opdivo) combined with one of three other drugs (rucaparib, docetaxel, or enzalutamide) in 292 men with advanced prostate cancer that had spread and stopped responding to hormone therapy. The goal was to see if these combinations could shrink tumors or lower PSA levels. Results from this completed Phase 2 trial will help decide which combinations to test further.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nivolumab (Opdivo) combined with either rucaparib, docetaxel, or enzalutamide
What this could lead to: If successful, this could point toward effective combination therapies for advanced prostate cancer that has stopped responding to standard hormone therapy.
What could go wrong: This is a completed Phase 2 trial, so results are preliminary and may not confirm benefit in larger studies. Side effects from combining these drugs could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CASTRATION RESISTANT METASTATIC PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Boston Medical Center

Boston, Massachusetts, 02118, United States
Local Institution - 0001

Essen, 45122, Germany
Local Institution - 0002

Jena, 07747, Germany
Local Institution - 0004

Heidelberg, D-69120, Germany
Local Institution - 0006

Göttingen, 37075, Germany
Local Institution - 0007

Koblenz, 56068, Germany
Local Institution - 0009

Marietta, Georgia, 30060, United States
Local Institution - 0010

Rancho Mirage, California, 92270, United States
Local Institution - 0011

St Louis, Missouri, 63110, United States
Local Institution - 0012

Detroit, Michigan, 48201, United States
Local Institution - 0013

Heidelberg, Victoria, 3084, Australia
Local Institution - 0014

South Brisbane, Queensland, 4101, Australia
Local Institution - 0015

Camperdown, New South Wales, 2050, Australia
Local Institution - 0016

Elizabeth Vale, South Australia, 5112, Australia
Local Institution - 0017

Westmead, New South Wales, 2145, Australia
Local Institution - 0018

Ijuí, Rio Grande do Sul, 98700-000, Brazil
Local Institution - 0019

Rio de Janeiro, Rio de Janeiro, 22793-080, Brazil
Local Institution - 0020

Belo Horizonte, Minas Gerais, 30110-022, Brazil
Local Institution - 0021

Porto Alegre, Rio Grande do Sul, 90035001, Brazil
Local Institution - 0022

Campinas, São Paulo, 13075-460, Brazil
Local Institution - 0024

Portland, Oregon, 97225, United States
Local Institution - 0025

Culiacán, Sinaloa, 80230, Mexico
Local Institution - 0026

Medellín, 0, Colombia
Local Institution - 0027

Montería, Departamento de Córdoba, 0, Colombia
Local Institution - 0029

Villejuif, 94800, France
Local Institution - 0030

Marseille, 13273, France
Local Institution - 0031

Lyon, 69008, France
Local Institution - 0032

Clermont-Ferrand, 63000, France
Local Institution - 0033

Besançon, 25030, France
Local Institution - 0034

Santiago, Santiago Metropolitan, 8420383, Chile
Local Institution - 0035

Omaha, Nebraska, 68130, United States
Local Institution - 0036

Daphne, Alabama, 36526, United States
Local Institution - 0037

Miami, Florida, 33176, United States
Local Institution - 0038

Albany, New York, 12208, United States
Local Institution - 0039

Fairfax, Virginia, 22031, United States
Local Institution - 0040

Rockville, Maryland, 20850, United States
Local Institution - 0041

Durham, North Carolina, 27710, United States
Local Institution - 0042

Capital Federal, Buenos Aires, 1426, Argentina
Local Institution - 0043

CABA, 1199, Argentina
Local Institution - 0044

Buenos Aires, Distrito Federal, C1280, Argentina
Local Institution - 0045

Madrid, 28041, Spain
Local Institution - 0046

Pamplona, 31008, Spain
Local Institution - 0047

Seville, 41013, Spain
Local Institution - 0048

Guadalajara, Jalisco, 44280, Mexico
Local Institution - 0049

New Haven, Connecticut, 06520, United States
Local Institution - 0050

Clayton, Victoria, 0, Australia
Local Institution - 0051

Viña del Mar, Valparaiso, 2540364, Chile
Local Institution - 0052

CABA, Buenos Aires, 1426, Argentina
Local Institution - 0053

Allentown, Pennsylvania, 18103, United States
Local Institution - 0054

León, Guanajuato, 37000, Mexico
Local Institution - 0055

Hamilton, Ontario, L8V 5C2, Canada
Local Institution - 0056

Québec, Quebec, G1J 1Z4, Canada
Local Institution - 0059

Moncton, New Brunswick, E1C 6Z8, Canada
Local Institution - 0061

Guadalajara, Jalisco, 44130, Mexico
Local Institution - 0062

Villa Siburu, Córdoba Province, 5003, Argentina
Local Institution - 0064

München, 81675, Germany
Local Institution - 0065

Louisville, Kentucky, 40207, United States
Local Institution - 0066

Montreal, Quebec, H2X 0C1, Canada
Local Institution - 0067

Kelowna, British Columbia, V1Y 5L3, Canada
Local Institution - 0068

New York, New York, 10032, United States
Local Institution - 0069

Jackson, Mississippi, 39202, United States
Local Institution - 0071

São Paulo, São Paulo, 05652-900, Brazil
Local Institution - 0073

São Paulo, São Paulo, 01308-050, Brazil
Local Institution - 0074

Belo Horizonte, Minas Gerais, 30130-090, Brazil
Local Institution - 0075

Curitiba, Paraná, 81480-580, Brazil
Tulane University

New Orleans, Louisiana, 70112, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.